Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

0.8638 -0.1662 (-16.14%)

Streaming Delayed Price Updated: 1:53 PM EDT, Jun 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 09, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces CEO Transition

May 09, 2022

From ADC Therapeutics SA

Via Business Wire

Earnings Outlook For ADC Therapeutics ↗

May 06, 2022

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...

Via Benzinga

ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

May 04, 2022

From ADC Therapeutics SA

Via Business Wire

Recap: ADC Therapeutics Q4 Earnings ↗

March 03, 2022

ADC Therapeutics (NYSE:ADCT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call ↗

May 04, 2022

ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to...

Via Benzinga

ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

May 03, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

April 04, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

March 17, 2022

From ADC Therapeutics SA

Via Business Wire

Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy' ↗

March 04, 2022

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating...

Via Benzinga

Earnings Preview For ADC Therapeutics ↗

March 02, 2022

ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

February 24, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

February 17, 2022

From ADC Therapeutics SA

Via Business Wire

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

February 08, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in Guggenheim Oncology Conference

February 02, 2022

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

January 20, 2022

From ADC Therapeutics

Via Business Wire

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan ↗

January 18, 2022

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize...

Via Benzinga

52 Biggest Movers From Friday ↗

January 18, 2022

Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...

Via Benzinga

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

January 18, 2022

From ADC Therapeutics SA

Via Business Wire

30 Stocks Moving In Friday's Mid-Day Session ↗

January 14, 2022

Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5....

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗

November 09, 2021

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:

Via Benzinga

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

November 09, 2021

From ADC Therapeutics

Via Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

November 04, 2021

From ADC Therapeutics SA

Via Business Wire

71 Biggest Movers From Yesterday ↗

November 03, 2021

Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...

Via Benzinga

ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

ADCT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 02, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

October 29, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

October 27, 2021

From ADC Therapeutics SA

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.